Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, discusses how the current regulatory climate is the result of years of work.
Gillian Woollett
Advertisement
Articles by Gillian Woollett
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
